Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs Essex Property Trust, Inc. (ESS) Price & Performance

BioNTech SE - ADRTrade
Essex Property Trust, Inc.Trade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs Essex Property Trust, Inc. — how do they compare? BioNTech SE - ADR trades at $90.53 (market cap $23.31B), while Essex Property Trust, Inc. trades at $282.11 (market cap $18.20B). The key difference: BioNTech SE - ADR is the larger of the two by market cap, and Essex Property Trust, Inc. pays a 3.66% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.

BNTXESS
Market Cap
$23.31B$18.20B
Sector
HealthReal Estate
52-Week High
$119.34$298.33
52-Week Low
$83.89$239.61
Enterprise Value
$6.60B$24.80B
Dividend Yield
3.66%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $93.67, up 2.72% today, with a bullish technical signal and strong analyst support. The stock faces fundamental challenges, including declining COVID-19 vaccine revenue and negative profitability, but holds a robust cash position of $16.78 billion. Recent news highlights leadership changes and pipeline advancements in oncology, with a consensus price target of $121.00 implying significant upside potential.

Outlook: Long-term growth hinges on oncology pipeline success, but near-term risks from vaccine demand volatility and net losses persist. Investment opportunity lies in discounted valuation relative to cash and pipeline assets, though execution risks and competitive pressures require careful monitoring.

Essex Property Trust, Inc.

ESS trades at $288.1, up 1.05% daily, with a neutral technical signal and support near $284. The stock shows strong profitability with a 21.48% net margin and recent Q2 2026 earnings miss on EPS but beat on FFO, leading to raised full-year guidance. Revenue growth is steady, reaching $1.89B in 2025, though net income declined to $670M from $742M in 2024.

Outlook is cautiously optimistic with a consensus price target of $305.86, implying ~6% upside. Risks include high debt levels (debt-to-asset ratio of 51.92% in 2024) and regional economic exposure. Analyst sentiment is mixed with 40% buy ratings, but institutional interest grew with Amundi increasing its stake in Q1 2026.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About Essex Property Trust, Inc.

Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.

Read more on ESS